Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525–535. doi:10.1038/nrclinonc.2014.122.
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015;62:855–862. doi:10.1016/j.jhep.2014.11.014.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739. doi:10.1016/S0140-6736(02)08649-X.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495–499. doi:10.1038/nature22396.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–752. doi:10.1038/nrc3581.
   PubMed Web of Science ®Google Scholar
• Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, Wang J, Song J, Zheng M, Sun H, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 2017;6:e1264562. doi:10.1080/2162402X.2016.1264562.
   PubMed Web of Science ®Google Scholar
• Stakheyeva M, Riabov V, Mitrofanova I, Litviakov N, Choynzonov E, Cherdyntseva N, Kzhyshkowska J. Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Curr Pharm Des. 2017;23:4807–4826. doi:10.2174/1381612823666170714161703.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016;5:e1188243. doi:10.1080/2162402X.2016.1188243.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer J-P, Liu J, Lim JS, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610–2620. doi:10.1172/JCI81603.
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu Y-X, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21:1209–1215. doi:10.1038/nm.3931.
   PubMed Web of Science ®Google Scholar
• Liu X, Kwon H, Li Z, Fu YX. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol. 2017;10:12. doi:10.1186/s13045-016-0381-z.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–285. doi:10.1016/j.cell.2009.05.046.
   PubMed Web of Science ®Google Scholar
• Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol. 2006;6:457–464. doi:10.1038/nri1859.
   PubMed Web of Science ®Google Scholar
• Navarro-Alvarez N, Yang YG. CD47: a new player in phagocytosis and xenograft rejection. Cell Mol Immunol. 2011;8:285–288. doi:10.1038/cmi.2010.83.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, et al. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci USA. 2017;114:10184–10189. doi:10.1073/pnas.1710776114.
   PubMed Web of Science ®Google Scholar
• Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, et al. Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9(381). pii:eaaf2968. doi: 10.1126/scitranslmed.aaf2968.
   Web of Science ®Google Scholar
• Ritchie DS, Smyth MJ. A new therapeutic target for leukemia comes to the surface. Cell. 2009;138:226–228. doi:10.1016/j.cell.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL. Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci USA. 2018;115:E1239–E48. doi:10.1073/pnas.1718197115.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med. 2018;379:1711–1721. doi:10.1056/NEJMoa1807315.
   PubMed Web of Science ®Google Scholar
• Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, Bennett ML, Olson A, Azad TD, Sinha R, et al. Microglia are effector cells of CD47-SIRPalpha antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci USA. 2019;116:997–1006. doi:10.1073/pnas.1721434116.
   PubMed Web of Science ®Google Scholar
• Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147:1393–1404. doi:10.1053/j.gastro.2014.08.039.
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin X-Y, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54:948–955. doi:10.1016/j.jhep.2010.08.041.
   PubMed Web of Science ®Google Scholar
• Kuang DM, Xiao X, Zhao Q, Chen MM, Li XF, Liu RX, Wei Y, Ouyang F-Z, Chen D-P, Wu Y, et al. B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets. J Clin Invest. 2014;124:4657–4667. doi:10.1172/JCI74381.
   PubMed Web of Science ®Google Scholar
• Liang S, Ma HY, Zhong Z, Dhar D, Liu X, Xu J, Koyama Y, Nishio T, Karin D, Karin G, et al. NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterology. 2019;156:1156–72 e6. doi:10.1053/j.gastro.2018.11.019.
   PubMed Web of Science ®Google Scholar
• Liu T, Larionova I, Litviakov N, Riabov V, Zavyalova M, Tsyganov M, Hoadley KA, Print C, Knowlton N, Black MA, et al. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology. 2018;7:e1436922. doi:10.1080/2162402X.2018.1490854.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12:1–4. doi:10.1038/cmi.2014.83.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585–600. doi:10.1007/s00281-013-0367-7.
   PubMed Web of Science ®Google Scholar
• Meng YM, Liang J, Wu C, Xu J, Zeng DN, Yu XJ, Hoadley KA, Print C, Knowlton N, Black MA, et al. Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma. Oncoimmunology. 2018;7:e1408745. doi:10.1080/2162402X.2018.1490854.
   PubMed Web of Science ®Google Scholar
• Chen DP, Ning WR, Li XF, Wei Y, Lao XM, Wang JC, Wu Y, Zheng L. Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy. 2018;14:1335–1346. doi:10.1080/15548627.2018.1474994.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr., van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–299. doi:10.1016/j.cell.2009.05.045.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109:6662–6667. doi:10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86–90. doi:10.1038/nature18935.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015;360:302–309. doi:10.1016/j.canlet.2015.02.036.
   PubMed Web of Science ®Google Scholar
• Lo J, Lau EY, So FT, Lu P, Chan VS, Cheung VC, Ching RHH, Cheng BYL, Ma MKF, Ng IOL, et al. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int. 2016;36:737–745. doi:10.1111/liv.12963.
   PubMed Web of Science ®Google Scholar
• Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, Ng IOL. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:179–191. doi:10.1002/hep.27070.
   PubMed Web of Science ®Google Scholar
• Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TKW. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62:534–545. doi:10.1002/hep.27859.
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327–1337. doi:10.1084/jem.20082173.
   PubMed Web of Science ®Google Scholar
• Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. The Lancet. 2008;371:961–963. doi:10.1016/S0140-6736(08)60428-6.
   PubMed Web of Science ®Google Scholar
• Felson DT. Tocilizumab versus adalimumab for rheumatoid arthritis. The Lancet. 2013;382:394–395. doi:10.1016/S0140-6736(13)61669-4.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li YL, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–231. doi:10.1126/science.aac9935.
   PubMed Web of Science ®Google Scholar
• Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roche H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, et al. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death Dis. 2019;10:199. doi:10.1038/s41419-019-1406-7.
   PubMed Web of Science ®Google Scholar
• Huang W, Wang WT, Fang K, Chen ZH, Sun YM, Han C, Sun L-Y, Luo X-Q, Chen Y-Q. MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47. Mol Cancer. 2018;17:12. doi:10.1186/s12943-018-0768-2.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Practice guidelines committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
   PubMed Web of Science ®Google Scholar
• Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou R-H, Lin X-J, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105:59–68. doi:10.1093/jnci/djs464.
   PubMedGoogle Scholar
• Labgaa I, Demartines N, Melloul E. Surgical resection vs. transarterial chemoembolization for intermediate stage hepatocellular carcinoma (BCLC-B): an unsolved question. Hepatology. 2019;69(2):923. doi:org/10.1002/hep.30338.
   PubMedGoogle Scholar
• Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol. 2011;26:1354–1360. doi:10.1111/j.1440-1746.2011.06812.x.
   PubMed Web of Science ®Google Scholar
• Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, Xiao G, Lin J, Zhuang S-M, Zhang Y-J, Zheng L. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018;119:80–88. doi:10.1038/s41416-018-0144-4.
   PubMed Web of Science ®Google Scholar
• Sun HY, Xu J, Huang M, Huang Q, Sun R, Xiao WH, Sun C. CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma. Immunol Lett. 2016;178:105–113. doi:10.1016/j.imlet.2016.08.009.
   PubMed Web of Science ®Google Scholar